Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) Target Price at $5.40

Context Therapeutics Inc. (NASDAQ:CNTX) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $5.6667.

Several research analysts have recently weighed in on CNTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, October 8th. Jones Trading assumed coverage on shares of Context Therapeutics in a report on Monday. They issued a “buy” rating and a $7.00 price target on the stock. D. Boral Capital reiterated a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Thursday, November 6th. Wall Street Zen upgraded Context Therapeutics to a “sell” rating in a research report on Saturday, November 22nd. Finally, HC Wainwright increased their target price on shares of Context Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Thursday, November 6th.

Context Therapeutics Trading Down 5.5%

Shares of Context Therapeutics stock opened at $1.20 on Thursday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $1.55. The business has a 50-day moving average price of $1.16 and a two-hundred day moving average price of $0.93. The company has a market cap of $110.26 million, a P/E ratio of -5.00 and a beta of 1.94.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Equities research analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Clear Harbor Asset Management LLC increased its holdings in Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after buying an additional 35,000 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Context Therapeutics during the third quarter worth $100,000. Finally, Vanguard Group Inc. increased its holdings in shares of Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock worth $3,387,000 after purchasing an additional 134,449 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.